In patients with IBD withdrawn from anti‐TNF therapy while in sustained remission, our meta‐analysis has shown a clinical relapse rate by 12 months of 39% for CD and 37% for UC/IBDU. This evidence concerns the gene TNF and inflammatory bowel disease.